FierceBiotech

ModeX nets up to $168M in BARDA bucks to develop therapies for viral infections

The big-time BARDA contracts keep rolling in, this time for infectious disease biotech and Merck partner ModeX Therapeutics. The company has hauled in a $168 million contract from the Biomedical ...
FierceBiotech

Regeneron pledges more than $1B biobucks for ModeX multispecific antibodies

Regeneron is buying in to Modex Therapeutics’ next-generation antibody platform with a $7 million upfront payment and a total potential deal value exceeding $1 billion. The New York-based biopharma ...
Yahoo Finance

OPKO Health’s ModeX Therapeutics Announces Epstein-Barr Virus Vaccine Candidate Enters Phase I Clinical Study in Collaboration with Merck

First participant dosed with novel investigational EBV vaccine targeting multiple viral proteins in Phase I study WESTON, Mass., Jan. 07, 2025 (GLOBE NEWSWIRE) -- ModeX Therapeutics Inc., an OPKO ...
Yahoo Finance

OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

Dr. Elias Zerhouni, ModeX Chairman, former President of Global R&D at Sanofi and former NIH Director, named President and Vice Chairman of OPKO Dr. Gary Nabel, ModeX President and CEO, former Chief ...
Nasdaq

ModeX Therapeutics Establishes Scientific Advisory Board to Enhance Development of Multispecific Antibodies for Complex Diseases

ModeX Therapeutics Inc., an OPKO Health company, announced the formation of a Scientific Advisory Board to support the development of its immunology and oncology pipeline, which includes ...